Novavax's full FDA approval for NUVAXOVID is a transformative milestone, unlocking a $175M Sanofi payment and validating their protein-based vaccine technology. The approval positions Novavax as the ...

The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years.

Novavax is undervalued, presenting an attractive risk-reward profile for long-term investors. Click here to find out why NVAX is a Buy.

Jefferies analysts said the approval was largely expected and an “incremental positive” for Moderna amid questions about the ...

Novavax received Food and Drug Administration approval for its new, protein-based COVID-19 vaccine, and shares jumped 25% at the opening bell Monday.

US regulators grant full approval to Novavax shot but sharply limit eligibility. New studies on heart risks required, raising concerns over future vaccine access. The US Food and Drug Administration ...

Novavax's shot is now fully approved in the U.S. Since 2022, the vaccine has been used under an emergency use authorization.

The vaccine, called Nuvaxovid, is mainly intended for adults 65 or older. But people ages 12 to 64 with medical conditions that increase their risk of serious illness from COVID can also get the shot.

Novavax’s shares traded nearly 20% in pre-market trading at the time of writing. The long-awaited approval for Nuvaxovid restricts its use to adults aged 65 and older. People aged between 12 and ...

The vaccine is expected to be commercially ready for the 2025-2026 COVID-19 season. The Food and Drug Administration (FDA) has approved Nuvaxovid ™ (COVID-19 Vaccine, Adjuvanted) for active ...

The U.S. Food and Drug Administration approved Novavax's COVID-19 vaccine with age restrictions after a six-week delay.